SAB Biotherapeutics Q3 2023 Earnings Report

SAB Biotherapeutics EPS Results

• Actual EPS: -$0.10
• Consensus EPS: -$0.10
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

SAB Biotherapeutics Revenue Results

• Actual Revenue: $1.27 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SAB Biotherapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/13/2023
• Time: N/A
• Conference Call Date: Tuesday, November 14, 2023
• Conference Call Time: 7:00AM ET

SAB Biotherapeutics (NASDAQ:SABS) is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases. SAB-185, its anti-SARS-CoV-2 polyclonal antibody candidate, advanced through clinical trials for the treatment and prevention of COVID-19. In addition to its coronavirus program, SAB Biotherapeutics is exploring pipeline candidates against other emerging pathogens, including Zika virus, MERS, and chikungunya virus. Beyond infectious disease, the Tc Bovine® platform has potential applications in oncology and chronic inflammatory conditions, where diverse antibody repertoires may address antigenic variation and tumor heterogeneity.

Since its founding in 2008, SAB Biotherapeutics has pursued strategic collaborations with government agencies, academic institutions, and industry partners to accelerate development of its antibody therapeutics. The company operates its biomanufacturing and research facilities in Sioux Falls and maintains collaborations across the United States for preclinical and clinical studies. By leveraging its transchromosomic cattle system, SAB Biotherapeutics aims to provide a rapid response capability for emerging public-health threats, while building a diversified pipeline of immune-based therapies for multiple indications.